Molecular Health Signs Distribution Agreement with TestAnalytika for Latin American Region

CAMBRIDGE, Massachusetts and HOUSTON, June 8, 2015 /PRNewswire/ --

Molecular Health signed an agreement with TestAnalytika to be its preferred distributor in the Latin American region at the 2015 ASCO Annual Meeting. TestAnalytika will begin to market and distribute Molecular Health's cancer treatment decision support product, TreatmentMAP™, to patients, physicians, hospitals, laboratories, cancer centers and insurers in Latin America later this year.

Molecular Health CEO Lutz Voelker said, "We are pleased that TestAnalytika will bring the best personalized cancer treatment decision support available, TreatmentMAP, to patients across Latin America as Molecular Health's preferred distributor in this region."  

TestAnalytika is bringing innovative integrated insurance solutions to the Latin American region to provide patients with access to advanced molecular genomic treatment support.  TestAnalytika will also support patients who prefer to prepay or self-pay for these services.  

TestAnalytika CEO Lin Giralt said, "TestAnalytika is going to provide cancer patients in Latin America with access to state of the art molecular cancer treatment decision support.  International patients will no longer need to travel to the U.S. or Europe to receive these kinds of services.  TestAnalytika will bring Molecular Health's TreatmentMAP to the patient's own physician enabling local personalized cancer treatment decisions."

TestAnalytika will launch these services in Latin America later this year.

About Molecular Health 

Molecular Health is a leading biomedical company that is transforming molecular data and medical knowledge into actionable clinical information for more efficient and safe cancer treatment options for each individual cancer patient. In the U.S., Molecular Health's TreatmentMAP™ is an end-to-end laboratory test grounded in next-generation sequencing technology.  TreatmentMAP™ generates an individualized tumor analysis for every patient and provides an interpretation of genomic patient data in a clinical context.  Molecular Health is an international company with its headquarters in Heidelberg, Germany and a laboratory and support center in Greater Houston, Texas and its U.S. corporate office in Cambridge, MA.  To learn more please visit: http://www.molecularhealth.com.    

About TestAnalytika 

TestAnalytika LLC is a start-up Houston, TX company led by its CEO, Lin Giralt and its COO, Zeke Wimert, both of whom have worked extensively in international markets. TestAnalytika has developed agreements with leading US Cancer Centers to provide Long Distance or Remote Cancer Advisory Services as well as with providers of other logistics, payment and support services and is also developing an internal HIPAA compliant IT platform to support this effort with the maximum of security and ease of use. It is closing agreements with various international insurance companies to write global policies that will include this Service among their policy benefits.  To learn more please visit: http://www.testanalytika.com.

For More Information 

Molecular Health:

Mark Rodgers: +1-832-247-3068 mark.rodgers@molecularhealth.com

TestAnalytika:

Lin Giralt: +1-713-447-1443 lin.giralt@testanalytika.com

Zeke Wimert: +1-832-392-8125 zeke.wimert@testanalytika.com